Global Heart Failure Drugs Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: August 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Heart Failure Drugs Market was valued at $14.8 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 10.8% CAGR, to an estimated market size of $24.7 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The global heart failure drugs market includes pharmaceutical therapies specifically indicated for the management of congestive heart failure (CHF), including Heart Failure with Reduced Ejection Fraction (HFrEF) and Heart Failure with Preserved Ejection Fraction (HFpEF). The scope covers drug classes such as ARNIs, SGLT2 inhibitors, beta-blockers, ACE inhibitors, ARBs, and diuretics, while excluding surgical devices and heart transplants.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Heart Failure Drugs Market in the period 2025-30:
- The rapid adoption of SGLT2 inhibitors and ARNIs is fundamentally reshaping treatment protocols due to superior clinical outcomes in reducing mortality.
- A rising global geriatric population is significantly expanding the patient pool susceptible to chronic cardiovascular conditions.
- Increased focus on HFpEF (Preserved Ejection Fraction) treatments is opening new market segments that were previously underserved by traditional therapies.
- The growing prevalence of comorbidities such as diabetes, obesity, and hypertension is acting as a primary driver for heart failure incidence.
- Advancements in diagnostic biomarkers and echocardiography are enabling earlier detection and initiation of pharmacological intervention.
- Expansion of online pharmacies and telemedicine is improving medication adherence and accessibility in emerging economies.
- Robust R&D investment and a strong pipeline of small molecules and biologics are expected to introduce novel therapeutic mechanisms by 2030.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Rest of World
Segments
- ARNIs
- Beta-blockers
- SGLT2 Inhibitors
- ACE Inhibitors & ARBs
- Others (Diuretics, MRAs, etc.)